Cancer Research and Treatment

Volume 34(5); October 2002

Original Articles

Survival of Korean Cancer Patients Diagnosed in 1995: Jong Myon Bae, Young Joo Won, Kyu Won Jung, Kyung Ae Suh, Young Ho Yun, Myung Hee Shin, Yoon Ok Ahn, Duk Hee Lee, Hai Rim Shin, Don Hee Ahn, Dae Kyu Oh, Jae Gahb Park; Cancer Res Treat. 2002;34(5):319-325. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.319

PURPOSE
To produce the nationwide 5-year survival rates of Korean cancer patients by primary cancer site.
MATERIALS AND METHODS
The study subjects were cancer patients diagnosed in 1995, as documented by the Korea Central Cancer Registry (KCCR) Program. This data was collected in 120 (93%) of 129 nationwide intern- and resident-training hospitals and 75 (94%) of the 80 Korean university hospitals. Follow-up was performed by obtaining information upon vital status (i.e., whether living or dead) from the government administered whole population files. Cumulative observed survival rate (OSR) was calculated by using the life table method and the relative survival rate (RSR) was computed using the life-time table for the years 1995, 1997, and 1999.
RESULTS
Of the 55,042 study subjects, the OSR for all Korean cancer patients was 61.4% at 1 year and 38.1% at 5 years. The RSR for all cancers was 62.5% at 1 year and 41.4% at 5 years, and the 5-year RSRs for all cancers in men and women were 32.6% and 53.2%, respectively.
CONCLUSION
This is the first nationwide report upon 5-year cancer survival by primary site in Korea. Men showed a lower survival rate than women in most malignancies. Pancreatic and thyroid cancer had the lowest and highest 5-year survival rates, respectively.

Citations

Citations to this article as recorded by

Survival of Stomach Cancer Cases in Khon Kaen, Thailand 2000-2012
Sirinya Nanthanangkul, Krittika Suwanrungruang, Surapon Wiangnon, Supannee Promthet
Asian Pacific Journal of Cancer Prevention.2016; 17(4): 2125. CrossRef
Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy
Seong Hyun Jeong, Jae Ho Jung, Jae Ho Han, Jang Hee Kim, Yong-Won Choi, Hyun Woo Lee, Seok Yun Kang, Yoon Ho Hwang, Mi Sun Ahn, Jin-Hyuk Choi, Young Taek Oh, Mison Chun, Seunghee Kang, Kwang Joo Park, Sung Chul Hwang, Seung Soo Sheen
Lung Cancer.2010; 68(2): 288. CrossRef
Effect of cancer diagnosis on patient employment status: a nationwide longitudinal study in Korea
Jae‐Hyun Park, Jong‐Hyock Park, Sung‐Gyeong Kim
Psycho-Oncology.2009; 18(7): 691. CrossRef
Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer
Seong Hyun Jeong, Jae Ho Jung, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Mi Sun Ahn, Yun Ho Hwang, Young Taek Oh, Jin-Hyuk Choi, Seung Soo Sheen, Kwang Joo Park
Journal of Lung Cancer.2009; 8(1): 8. CrossRef
Investigating Effective Combinations of Anti-cancer Drugs and Radiation Therapy for Treating Non-small Cell Lung Cancer with Using Two Cell Lines
In-Jae Oh, Hyun-Ju Cho, Tseden-Ish Manaljav, Yong-Soo Kwon, Kyu-Sik Kim, Sung-Chul Lim, Young-Chul Kim, Sung-Ja Ahn
Journal of Lung Cancer.2009; 8(1): 21. CrossRef
What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea?
Sang Min Park, Sun-Young Kim, Craig C Earle, Seung-Yong Jeong, Young Ho Yun
World Journal of Gastroenterology.2009; 15(25): 3153. CrossRef
Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous Histology
S. H. Jeong, H.-W. Lee, J. H. Han, S. Y. Kang, J.-H. Choi, Y. M. Jung, H. Choi, Y. T. Oh, K. J. Park, S. C. Hwang, S. S. Sheen, Y. J. Oh, J. H. Kim, H.-Y. Lim
Japanese Journal of Clinical Oncology.2008; 38(10): 661. CrossRef
Comparison of Cancer Survival by Age Group for 1997 and for 2002: Application of Period Analysis using the National Cancer Incidence Database
Seon-Hee Yim, Kyu-Won Jung, Young-Joo Won, Hyun-Joo Kong, Hai-Rim Shin
Journal of Preventive Medicine and Public Health.2008; 41(1): 17. CrossRef
Socio-economic status and the risk of liver cancer mortality: A prospective study in Korean men
S. Joshi, Y.-M. Song, T.-H. Kim, S.-I. Cho
Public Health.2008; 122(11): 1144. CrossRef
Job Loss and Re-Employment of Cancer Patients in Korean Employees: A Nationwide Retrospective Cohort Study
Jae-Hyun Park, Eun-Cheol Park, Jong-Hyock Park, Sung-Gyeong Kim, Sang-Yi Lee
Journal of Clinical Oncology.2008; 26(8): 1302. CrossRef
Cancer Survival in Korea 1993-2002: A Population-Based Study
Kyu-Won Jung, Seon-Hee Yim, Hyun-Joo Kong, Soon-Young Hwang, Young-Joo Won, Jong-Koo Lee, Hai-Rim Shin
Journal of Korean Medical Science.2007; 22(Suppl): S5. CrossRef
Population-based Breast Cancer Statistics in Korea during 1993-2002: Incidence, Mortality, and Survival
Jin-Hee Lee, Seon-Hee Yim, Young-Joo Won, Kyu-Won Jung, Byung Ho Son, Hy-De Lee, Eun-sook Lee, Keun-Young Yoo, Sei Hyun Ahn, Hai-Rim Shin
Journal of Korean Medical Science.2007; 22(Suppl): S11. CrossRef
The Role of Heme Oxygenase-1 in Lung Cancer Cells
Jong-Hoon Jung, Hak-Ryul Kim, Eun-Jung Kim, Ki-Eun Hwang, So-Young Kim, Jung-Hyun Park, Hwi-Jung Kim, Sei-Hoon Yang, Eun-Taik Jeong
Tuberculosis and Respiratory Diseases.2006; 60(3): 304. CrossRef
Feasible economic strategies to improve screening compliance for colorectal cancer in Korea
Sang Min Park
World Journal of Gastroenterology.2005; 11(11): 1587. CrossRef
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas
Young Hwa Soung, Jong Woo Lee, Su Young Kim, Yong Jik Sung, Won Sang Park, Suk Woo Nam, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee
Oncogene.2005; 24(1): 141. CrossRef
Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea
S. H. Jee, H. Ohrr, J. W. Sull, J. M. Samet
JNCI Journal of the National Cancer Institute.2004; 96(24): 1851. CrossRef
A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting
Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee
Cancer Research and Treatment.2004; 36(5): 287. CrossRef
Lung Cancer : Overview
Jin Soo Lee
Journal of the Korean Medical Association.2003; 46(1): 7. CrossRef

4,521 View
24 Download
18 Crossref

The Effect of Intensified Induction Using Vanderbilt Regimen in Patients with an Intermediate Grade Non-Hodgkin's Lymphoma Having 2 or 3 Adverse Factors on the Age-adjusted International Prognostic Index: Yoong Ju Kweon, Seong Jun Choi, Baek Yeol Ryoo, Yeon Hee Park, Bong Seog Kim, Dae Han Kim, Sang Il Kim, Sung Ho Kim, Yo Ahn Suh, Hyun Bae Son, Kui Sung Choi, Seung Sook Lee, Yoon Koo Kang; Cancer Res Treat. 2002;34(5):326-333. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.326

Abstract PDF: PURPOSE
The purpose of our study was to evaluate the outcome of intensified induction therapy using the Vanderbilt regimen in patients with a poor prognosis non-Hodgkin's lymphoma (NHL).
MATERIALS AND METHODS
We retrospectively analyzed the results of two pilot studies, which enrolled the patients aged 60 years or less, with a previously untreated NHL of intermediate grade on the Working formulation, having 2 or 3 adverse prognostic factors on the age- adjusted International Prognostic Index. Patients received an intensified induction, with the regimen described by the Vanderbilt group.
RESULTS
Thirty-five patients were analyzed. After induction, 29 patients (83%) achieved more than partial response (PR): 22 (63%) complete response (CR) and 7 (20%) PR. Three of the PRs were subsequently converted to CR following consolidation therapy. The overall CR rate, following the completion of treatment, was 71%. The 3-year overall survival (OS) rate of all patients was 53%. In the univariate analysis, age (50 years) was the only factor affecting the OS. The 3-year disease-free survival (DFS) rate of patients with CR was 68%. In the univariate analysis, age and bone marrow involvement were the factors affecting the DFS. Two patients died from the treatment-related toxicity of the induction therapy: one due to sepsis and the other due to congestive heart failure.
CONCLUSION
Although the CR rate was relatively high, the OS or DFS of patients with a poor prognosis NHL, who had received the intensified induction using the Vanderbilt regimen, were no different from those that had received the conventional chemotherapy, as reported by the International Prognostic Index Project. However, the OS or DFS in the young patient groups were encouraging. To test the hypothesized benefits of our approach in the young patient groups, a larger cohort of patients aged 50 years or less should be studied.

3,853 View
23 Download

Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer: Chul Kim, Joo Hyuk Sohn, Joo Hang Kim, Se Kyu Kim, Young Sam Kim, Joon Chang, Jae Yong Cho; Cancer Res Treat. 2002;34(5):334-338. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.334

Abstract PDF

PURPOSE
Refractory small-cell lung cancer (SCLC) has a poor prognosis, and current salvage chemotherapy for refractory SCLC, such as CAV (cyclophosphamide, adriamycin, vincristine) or topotecan, has an unsatisfactory outcome, with a response rate and overall survival of less than 10% and 6 months, respectively. This phase II study evaluated the role of topotecan combined with etoposide in SCLC patients that have progressed, or relapsed, within 3 months following completion of the initial chemotherapy.
MATERIALS AND METHODS
Twenty-seven patients were entered into this study. Eligible patients had an ECOG performance status of less than, or equal to, 2, at least one bidimensionally measurable lesion and adequate end organ function. IV topotecan, 1.0 mg/m2/d for 5 consecutive days, and etoposide, 100 mg/m2/d through days 1 to 3, were administered every 3 weeks until disease progression or undue toxicity.
RESULTS
The major toxicity was myelosuppression. Grade 3/4 anemia, granulocytopenia, and thrombocy-topenia occurred in 14.2, 34.8, and 27.3% of cycles, respectively. There was no treatment-related death, and other non-hematologic toxicities were generally mild. Four patients achieved partial responses, with a response rate RR of 14.8%. The progression-free survival PFS ranged from 1 to 7 months, with a median of 2.0 months (95% confidence interval 1.22~2.78 months). Twenty-five patients died, with a median overall survival of 5.5 months (ranging from 1 to 21 months, 95% CI 4.32~6.68 months), and the 6-month survival rate was 32.1% (95% confidence interval 14.4~49.8%).
CONCLUSION
The combination of topotecan and etoposide chemotherapy showed a modest response rate, but failed to prolong survival of refractory SCLC patients compared to topotecan monotherapy.

Citations

Citations to this article as recorded by

Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
Joo Sung Shim, Youhyun Kim, Taeho Yuh, Jii Bum Lee, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
Lung Cancer: Targets and Therapy.2024; Volume 15: 149. CrossRef

4,268 View
28 Download
1 Crossref

actate Dehydrogenase (LDH) as a Tumor Marker for Non-small Cell Lung Cancer: Young Jin Yuh, Sung Rok Kim; Cancer Res Treat. 2002;34(5):339-344. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.339

Abstract PDF

PURPOSE
To determine the prognostic value of pre- treatment serum LDH levels and the LDH isoenzyme pattern for non-small cell lung cancer, and to determine the relationship between the response to chemotherapy and the changes in serum LDH levels following chemotherapy MATERIALS AND METHODS: Patients with pathologically confirmed non-small cell lung cancer were entered onto this study. Their serum LDH levels were assessed prior to chemotherapy, with the LDH isoenzyme being assessed in patients with high initial serum LDH levels. The serum LDH levels were re-assessed following 2 cycles of chemotherapy. The relationship between the response to chemotherapy, pre-treatment serum LDH levels and LDH isoenzyme pattern and the changes in serum LDH levels, following chemotherapy, were evaluated.
RESULTS
49 patients were entered onto this study. The pre-treatment serum LDH levels were normal in 26 patients, and elevated in 23. The LDH isoenzyme was evaluated in 15 patients, with LDH2 being elevated the most frequently. The response rate to chemotherapy was 42.9% in all 42 patients able to be evaluated, 45.8% in patients with normal serum LDH levels and 41.2% in patients with elevated serum LDH levels. This difference was not statistically significant (p=0.767). The median survival was 37 weeks in all patients able to be evaluated, 38 weeks in those with normal serum LDH levels and 31 weeks in those with elevated serum LDH levels. These differences were not statistically significant (p=0.202). The patients with normal serum LDH levels following chemotherapy were more responsive to chemotherapy than those with elevated serum LDH levels following chemotherapy (response rate 51.4% vs. 0%, p=0.027).
CONCLUSION
The LDH2 are most commonly elevated in non small cell lung cancer patients. The pre-treatment serum LDH levels do not reflect the prognosis accurately. The serum LDH levels following chemotherapy are associated with the response to chemotherapy.

Citations

Citations to this article as recorded by

Nomogram combining clinical and radiological characteristics for predicting the malignant probability of solitary pulmonary nodules measuring ≤ 2 cm
Mengchao Xue, Rongyang Li, Kun Wang, Wen Liu, Junjie Liu, Zhenyi Li, Zheng Ma, Huiying Zhang, Hui Tian, Yu Tian
Frontiers in Oncology.2023;[Epub] CrossRef
Serum lactate dehydrogenase activities as systems biomarkers for 48 types of human diseases
Yuling Wu, Caixia Lu, Nana Pan, Meng Zhang, Yi An, Mengyuan Xu, Lijuan Zhang, Yachong Guo, Lijuan Tan
Scientific Reports.2021;[Epub] CrossRef
Nedaplatin as a Single-Agent Chemotherapy May Support Palliative Therapy for Patients with Adenoid Cystic Carcinoma: A Case Report
Hiroyuki Hirakawa, Takayoshi Kiba, Yuko Saito, Yoshiteru Watanabe, Takahiro Suzuki, Nobuo Ota
Case Reports in Oncology.2017; 10(2): 783. CrossRef
Tumor Lysis Syndrome Induced by Radiotherapy in Non-Small Cell Lung Cancer
Dong-Hyo Noh, Ki-Eun Hwang, Jeong-Hyun Shin, Dong Kim, Kyung-Hwa Cho, Keum-Ha Choi, Seong-Hoon Park, Eun-Taik Jeong, Hak-Ryul Kim
Journal of Lung Cancer.2010; 9(2): 106. CrossRef

6,344 View
73 Download
4 Crossref

Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Sang wook Lee, Eun Kyung Choi, Suk Joong Oh, Cheol Won Suh, Sang We Kim, Jung Shin Lee, Dong Soon Kim, Won Dong Kim, Woo Seong Kim, Sang Do Lee, Jong Hoon Kim, Seung Do Ahn, Kyoung Ju Kim, Young Ju Noh; Cancer Res Treat. 2002;34(5):345-351. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.345

Abstract PDF

PURPOSE
To investigate the feasibility, toxicity and response rate, of concurrent chemoradiation therapy with paclitaxel/cisplatin in stage III locally advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between May 1999 and December 2000, 80 patients with stage III NSCLC were enrolled in a prospective protocol. Radiotherapy was given to a total dose of 70.2 Gy (daily fraction of 1.8 Gy for 5 days), over an 8 week period, on the gross tumor volume, combined with chemotherapy. The concurrent chemotherapy consisted of paclitaxel (40 mg/m2) and 20 mg/m2 cisplatin per week for 8 consecutive weeks. All patients received 3-D conformal radiotherapy using CT-simulated planning. Acute toxicities were evaluated by the RTOG scale. The median follow-up period was 16 months, ranging from 3 to 29 months.
RESULTS
Of the 80 patients, 71 received treatment per protocol, with minor variation of protocol delivery. The median age of the patients was 60 years. Karnofsky Performance status were 100 and 90 in 62 patients, and 80 and 70 in 9, respectively. Weight loss of less than 5% for 6 months was observed in 22 patients. The response to treatment was evaluated from the radiological findings. Complete and partial responses were observed in 8 and 51 patients, respectively. Ultimately, 82% of patients (included complete responses: 8 cases) obtained more than a partial response. Although, radiation induced esophagitis was the most common treatment related toxicity, occurring in 44 patients (69%), severe radiation esophagitis like, grade 3, was observed in only 3 patients, and the most acute toxicities had completely recovered 1 month following treatment. The overall 2-year actuarial and progression free survivals were 56 and 45%, respectively.
CONCLUSION
This combined modality has activity with manageable toxicity and 23 months in mean survival time in patients with stage III NSCLC. A longer follow up will be required to realise the expected higher survival of these results.

Citations

Citations to this article as recorded by

A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
Cancer Research and Treatment.2004; 36(5): 293. CrossRef

4,364 View
18 Download
1 Crossref

Effect of Vinorelbine, Ifosfamide and Cisplatin Combination Chemotherapy in Stage III-IV Non-Small-Cell Lung Cancer: Young Chul Kim, So Young Lee, Hong Joo Cho, Jung A Kim, So Hyang Song, Chi Hong Kim, Hoon Kyo Kim, Meyung Im Ahn, Jin Young You, Sung Whan Kim, Deng Gon Cho, Kyu Do Cho, Jin Hyung Kang; Cancer Res Treat. 2002;34(5):352-356. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.352

Abstract PDF: PURPOSE
To evaluate the response rates, toxicitiesy, and survival rates, to vinorelbine (Navelbine(R)), cisplatin and ifosfamide combination chemotherapy, of the patients with inoperable NSCLC (stage III and IV), who received vinorelbine (Navelbine(R)), cisplatin, ifosfamide combinationthe mentioned chemotherapy every 4 weeks.
MATERIALS AND METHODS
This study included 26 patients with inoperable NSCLC (stage III and IV), who attended St. Vincent's Hospital Bbetween April 1999 and December 2001, 26 patients were included at St.Vincent's Hospital. The chemotherapy regimen consisted of vinorelbine (25 mg/m2 on days 1 and 8), ifosfamide (1,500 mg/m2 on days 1- and 2 with mesna), and cisplatin (30 mg/m2 on days 1- to 3). The cycles were administered every 4 weeks. A 25% reduction in the doses reduction was applied into subsequent courses if there werewas grade 3~4 neutropenia.
RESULTS
The median age was 63 (range, 44~73) years and the male : to female ratio was 19 : 7. One patient had stage IIIa, 6 had stage IIIb and 19 had stage IV. Twenty two patients had an ECOG performance status of 0 or 1, andwith 4 hadhave one of 2. Eighteen of the patients had adenocarcinoma, 7 had squamous cell carcinomas, and 1 had an undifferentiated NSCLC. Two patients were innot able to be evaluatedble due to follow-up loss. Among Of the 24 patients able to be evaluatedble patients, 1 patient had a complete response and 9 patients hada partial responses, and thewith an overall response rate wasof 41.7%. During a total of 104 cycles, grade 3 neutropenia occurred in 29%, grade 4 neutropenia in 12%, grade 3~4 thrombocytopenia in 4%, grade 3 anemia in 11%, and grade 3~4 mucositis in 2%. The mean time to progression was 6.4 months (range 1~13) and the median overall survival was 10 months (range 1.5~32).
CONCLUSION
The combination of vinorelbine, ifosfamide and cisplatin, in the dose and schedule employed in this study, shows an response rate of 41.7%, but, because grade 3- or 4 neutropenia occurred in 41%, a careful investigation is needed.

4,572 View
31 Download

Polymorphisms of p53, p21 and IRF-1 and Cervical Cancer Susceptibility in Korean Women: Sung Jong Lee, Sung Eun Namkoong, Won Chul Lee, Jae Woong Sul, Sun Ha Jee, Youn Kyoung You, Jong Eun Lee, Jong Sup Park; Cancer Res Treat. 2002;34(5):357-364. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.357

Abstract PDF

PURPOSE
The aim of this study was to identify gene- gene and gene-environmental factor on cervical carcinogenesis in Korean women.
MATERIALS AND METHODS
We evaluated 185 women patients who had cervical cancer with 345 normal control healthy women. The single nucleotide polymorphisms (SNPs) of the p53 codon 72, the p21 codon 31 and the IRF-1 intron 6 were evaluated from extracted DNA of peripheral blood with an automatic DNA sequencer. The difference of each SNP, gene-gene and gene-environmental interaction between normal controls and patients, were evaluated in an adjusted environmental background.
RESULTS
With regard to environmental factors, the cervical cancer increased in the women with a lower level of education, a younger age at first sexual intercourse and with the increased number of children borne. The women who had p53 (Arg/Arg), IRF-1 (T/T) and an education of less than 6 years showed a 14.7 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and an education of more than 15 years. The women who had p53 (Arg/Arg), p21 (Ser/Ser) and more than 3 children showed a 6.4 fold increased risk of cervical cancer than those women who had p53 (~Pro), p21 (~Arg) and had borne no child. The women who had p53 (Arg/Arg), IRF-1 (T/T) and had experience of first sexual intercourse before the age of 22-years showed a 5.5 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and had experience of first sexual intercourse after the age of 26-years.
CONCLUSION
We found that the level of education, the age at first intercourse, and the number of children borne, were independent risk factors in cervical carcinogenesis. The specific combination of p53, p21 and IRF-1 gene-gene and gene-environmental interactions were significantly noted in the cervical carcinogenesis of Korean women.

Citations

Citations to this article as recorded by

Distinctive cell cycle regulatory protein profiles by adenovirus delivery of p53 in human papillomavirus-associated cancer cells
H.-S. JIN, S.-M. BAE, Y.-W. KIM, J.-M. LEE, S.-E. NAMKOONG, B.-D. HAN, Y.-J. LEE, C.-K. KIM, H.-J. CHUN, W.-S. AHN
International Journal of Gynecological Cancer.2006; 16(2): 698. CrossRef
Cell Cycle Regulatory Protein Expression Profiles by Adenovirus p53 Infection in Human Papilloma Virus-associated Cervical Cancer Cells
Yong-Seok Lee, Su-Mi Bae, Sun-Young Kwak, Dong-Chun Park, Yong-Wook Kim, Soo-Young Hur, Eun-Kyung Park, Byoung-Don Han, Young-Joo Lee, Chong-Kook Kim, Do Kang Kim, Woong-Shick Ahn
Cancer Research and Treatment.2006; 38(3): 168. CrossRef
Cellular process classification of human papillomavirus-16-positive SiHa cervical carcinoma cell using Gene Ontology
W. S. Ahn, M.-J. Seo, S. M. Bae, J. M. Lee, S. E. Namkoong, C. K. Kim, Y.-W. Kim
International Journal of Gynecological Cancer.2005; 15(1): 94. CrossRef

4,772 View
30 Download
3 Crossref

Results of Curative Radiotherapy Alone in Patients with Uterine Cervical Carcinomas: Taek Keun Nam, Byung Sik Nah, Sung Ja Ahn, Woong Ki Chung, Ho Seon Choi, Yoon Kyeong Oh; Cancer Res Treat. 2002;34(5):365-371. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.365

Abstract PDF: PURPOSE
To evaluate the role of curative radiotherapy alone in the treatment of uterine cervical carcinomas, by a retrospective analysis with respects to survival and pelvic control, and to find any risk factors of failure MATERIALS AND METHODS: Between Jan. 1990 and Dec. 1995, a total of 187 patients, diagnosed with uterine cervical carcinomas in FIGO stages greater than IA, were treated by curative radiotherapy alone with no chemotherapy. The ages of the patients ranged from 26 to 80 years, with a median of 60 years. The number of patients diagnosed with squamous cell carcinomas were 183 (97.9%). The number of patients with FIGO stage IB1, IB2, IIA, IIB, IIIA, IIIB and IVA were 61 (32.6%), 7 (3.7%), 43 (23.0%), 62 (33.3%), 3 (1.6%), 7 (3.7%) and 4 (2.1%), respectively. External radiotherapy was performed with 6 MV or 10 MV X-rays, with a dose range of 19.8 Gy~ 50.4 Gy (median; 30.6), to whole pelvis. Intracavitary radiation (ICR) was then performed using a high-dose rate remote controlled afterloader with radioisotopes of Co-60 and Cs-137. The fraction size of the ICR was 5 Gy twice a week, and was delivered up to total doses of 10 Gy~ 55 Gy (median; 40). After the ICR, additional pelvic external radiotherapy with midline shielding width of 4 cm was performed with the dose range of 0~30.6 Gy (median; 19.8), and the resultant total doses of A points ranged between 49.8 Gy and 86.0 Gy (median; 70.6).
RESULTS
The five-year overall survival rates of FIGO IB1, IB2, IIA, IIB, III and IVA were 88.3%, 83.3%, 86.1%, 65.2%, 60.0% and 50.0%, respectively (p=0.005). The pelvic control rates of each stage were 90.1%, 85.7%, 86.1%, 69.4%, 68.6% and 50.0%, respectively (p=0.03). From the multivariate analysis, the radiation response and tumor diameter were found to be significant factors affecting the overall survival. The significant factors influencing pelvic control were the radiation response and pre-treatment hemoglobin level.
CONCLUSION
The radiation response and tumor diameter were significant factors affecting survival, so patients with tumor diameters greater than 4 cm should be considered for a combined modality, such as concurrent chemoradiotherapy.

4,433 View
21 Download

Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro: Ji Hyun Jang, Sang Hak Lee, Jin Hyoung Kang, Hee Sik Sun, Kazuto Nishio, Nagahiro Saijo, Hyo Jeong Kuh; Cancer Res Treat. 2002;34(5):372-381. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.372

Abstract PDF

PURPOSE
Oxaliplatin (LOHP), 5-FU, and paclitaxel (PTX) are considered highly active against advanced gastric carcinomas, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839 is considered as a good candidate for the treatment of gastric cancers when given alone or in combination with cytotoxic agents. The present study evaluated the antitumor effects of these agents in SNU-1 human gastric cancer cells either alone or when given as a doublet (i.e., as a cytotoxic-cytostatic combination).
MATERIALS AND METHODS
We selected SNU-1 cells that showed DNA mismatch repair (MMR) deficiency and EGFR overexpression. Growth inhibition was measured by MTT and by direct cell counting and cell cycle distribution by flow cytometry. The combination index (CI) was used to describe synergistic interaction.
RESULTS
The four drugs showed IC50s ranging from 1.81 nM to 13.2microM. MTT assay appeared to underestimate the cytotoxicity of PTX, which was attributed to a significant resistant fraction (32%). LOHP and PTX induced G2/M arrest, 5-FU increased in S phase, and ZD1839 in-creased in G1 in a concentration dependent manner. PTX ZD1839 showed the greatest synergism and LOHP ZD1839 showed a similar result. The cell cycle effect of PTX was potentiated by the coadministration of ZD1839. A previously developed cytostatic TPi model was used to assess the contribution of cell cycle arrest to overall growth inhibition, and 64% and 80% of the overall growth inhibition was attributed to cell cycle arrest for LOHP and PTX, when exposed to 7.55microM and 10 nM for 72 hr, respectively.
CONCLUSION
This study demonstrates the antitumor activity and significant cell cycle arrest effect of ZD1839 against human gastric carcinoma cells and its synergistic interaction with LOHP and PTX. These results provide a preclinical rationale for the clinical development of ZD1839 and its use in combination with LOHP or PTX against human gastric cancers that express EGFR.

Citations

Citations to this article as recorded by

Connecting Agent-Based Models with High-Dimensional Parameter Spaces to Multidimensional Data Using SMoRe ParS: A Surrogate Modeling Approach
Daniel R. Bergman, Kerri-Ann Norton, Harsh Vardhan Jain, Trachette Jackson
Bulletin of Mathematical Biology.2024;[Epub] CrossRef
A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study
Marisa C. Eisenberg, Harsh V. Jain
Journal of Theoretical Biology.2017; 431: 63. CrossRef

5,073 View
37 Download
2 Crossref

Salvage Treatment for Advanced Gastric Cancer Using FEP (5-FU, Etoposide, Cisplatin) Combination Chemotherapy: Je Hyuk Chung, Yee Zee Bae, Sung Hyun Kim, Chang Hoon Moon, Jun Young Chung, Hyuk Chan Kwon, Jae Seok Kim, Hyo Jin Kim; Cancer Res Treat. 2002;34(5):382-387. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.382

Abstract PDF

PURPOSE
There is no effective treatment for patients with advanced gastric cancer having failed to respond to first line chemotherapy. The aim of this study was to evaluate the therapeutic activity, and safety, of a FEP regimen in patients with a recurrence of, or metastatic, gastric cancer that had been unresponsive to primary chemotherapy.
MATERIALS AND METHODS
Recurred or metastatic gastric cancer patients that did not respond to a 5-fluorouracil based regimen were entered into this trial. The patients were treated with FEP (5-FU, etoposide and cisplatin) as salvage chemotherapy. The treatment regimen was 5-FU (900 mg/m2/day) by continuous infusion for 3 days, etoposide (90 mg/m2/day) on days 1, 2 and 3, and cisplatin (60 mg/m2/day) on day 2. This treatment was repeated every 3 weeks.
RESULTS
Between December 1997 and October 2001, 28 patients were enrolled to the study. The response rate was 32.1% (95% CI 15.5~57.8%). The median times to progression and survival duration were 23~33 weeks, respectively. Among a total of 187 cycles of chemotherapy, the grade 3 and 4 hematological toxicities were leukopenia (6.4%), thrombocytopenia (1.6%), and grade 3 non-hematological side effects of nausea/vomiting (17.9%).
CONCLUSION
FEP combination chemotherapy seems to be an effective treatment regimen for gastric cancer as salvage chemotherapy. To confirm these results, large scale of clinical trials will be required.

Citations

Citations to this article as recorded by

Anticancer Effect of a Novel Octahydropyrazino[2,1-a:5,4-a′]diisoquinoline Derivative and Its Synergistic Action with Nigella sativa in Human Gastric Cancer Cells
Anna Czajkowska, Agnieszka Gornowicz, Natalia Pawłowska, Robert Czarnomysy, Jolanta Nazaruk, Wojciech Szymanowski, Anna Bielawska, Krzysztof Bielawski
BioMed Research International.2017; 2017: 1. CrossRef
The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy
Sang-Joon Shin, Min-Kyoung Kim, Kyung-Hee Lee, Myung-Soo Hyun, Sang Woon Kim, Sun Kyo Song, Sung-Hwa Bae, Hun-Mo Ryoo
Cancer Research and Treatment.2004; 36(6): 367. CrossRef

5,375 View
26 Download
2 Crossref

Interrelation of Cyclin D1, Cyclin E, and p27Kip1 Expression on Tissue Arrays of Breast Cancer: Se Hwan Han, Kyeong Mee Park, Byung Noe Bae, Suk Yong Ryu, Ki Hwan Kim, Hong Joo Kim, Young Duck Kim, Hong Yong Kim; Cancer Res Treat. 2002;34(5):388-393. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.388

Abstract PDF

PURPOSE
To evaluate the clinical impact of the altered expression of cell cycle regulators in stage I and II breast cancers.
MATERIALS AND METHODS
The interaction between cyclin D1/E and p27Kip1 expressions were analyzed using tissue microarray (TMA) technology in 133 breast cancers. Data from the immunohistochemical assays of 3 molecules were merged, and analyzed, with a Ki67 labeling index of the same tumors.
RESULTS
Cyclin D1 was expressed in 72 breast carcinomas (54.1%) and cyclin E in 60 (45.1%) out of the 133 breast carcinomas. Expressions of cyclin D1 and cyclin E were inversely related to each other, and significantly associated with the estrogen receptor (ER) expression and differentiation of the breast carcinoma. The expression of cyclin E was significantly decreased in tumors expressing cyclin D1 (p=0.022). There was a trend for cyclin D1 expression to increase in tumors expressing p27Kip1 (p=0.053), but the expression of cyclin E did not correlate with p27Kip1 expression. The Ki67 labeling index was markedly increased in tumors expressing cyclin E, whereas it was significantly decreased in the cyclin D1 or p27Kip1 expressing-tumors. From survival analysis, cyclin E expression was the only significant variable for the prediction of poor survival.
CONCLUSION
The abnormal expressions of cell cycle regulatory molecules are prevalent, and interrelated with each other in breast cancer. Integration of TMA technology allowed a high-throughput analysis for correlating molecular the in situ findings, with the clinico-pathologic information. Among the three molecules studied, the cyclin E had a prognostic implication for stage I and II breast cancer.

Citations

Citations to this article as recorded by

Novel insights into biomarkers of progression in Desmoid tumor
Baiqi Liu, Zefang Sun, Rui Zhou, Dingcheng Shen, Shuai Zhu, Lu Chen, Gengwen Huang
Frontiers in Oncology.2023;[Epub] CrossRef

3,547 View
16 Download
1 Crossref

Metastasis to the Thigh Skeletal Muscle from an Adenocarcinoma of the Duodenum: Hyo Wook Gil, Jong Ho Won, Nam Su Lee, Sang Cheol Lee, So Eun Kim, Chan Kyu Kim, Kyu Taeg Lee, Sung Kyu Park, Seung Ho Baick, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2002;34(5):394-396. Published online October 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.5.394

Abstract PDF: Skeletal muscle is one of the most unusual metastatic sites for any malignancy. Duodenal cancer is extremely rare, and no cases of skeletal muscle metastasis from duodenal cancer have been reported. We report here in a case of metastasis to the skeletal muscle of the left thigh from duodenal cancer. Our patient was a 47-year-old man, exhibiting a painful mass in the posterior aspect of his left thigh over a 4 month period. An imaging study, and a biopsy, revealed a duodenal adenocarcinoma metastasize to the skeletal muscle. The patient refused chemotherapy and has followed up for 4 months.

4,083 View
22 Download

First
Prev
Page of 1
Next
Last

Previous issues